title: [Radiofrequency ablation and percutaneous ethanol injection in patients with unresectable hepatocellular carcinoma--a comparative study using Japan Integrated Staging Score (JIS score) system].
abstract: The patients were classified according to the Japan Integrated Staging (JIS) score and a comparison examination of the long-term therapeutic response of 149 unresectable hepatocellular carcinomas: 90 of them given percutaneous ethanol injection (PEI), and 59 of them given radiofrequency ablation (RFA) who were diagnosed with 3 cm or less in diameters of tumor and less than three nodules, or 5 cm or less single nodule, was carried out in retrospective. To all the tumors exceeding 3 cm in diameter, we added transcatheter arterial embolization (TAE) prior to PEI or RFA. Ninety four percent of PEI cases and 25% of RFA cases received a combination therapy with TAE, respectively. The three-year survivals were 86%, 76%, and 56% in PEI and 96%, 83%, and 68% in RFA for JIS-0, 1, and 2, respectively. The five-year survivals were 69% and 53% in PEI and 95% and 83% in RFA for JIS-0 and 1, respectively. The significant difference in the probability of survival was not confirmed among both treatments. We conclude that the combination therapy, such as combined use of TAE, PEI and RFA as local treatment, can expect almost equivalent effectiveness for unresectable hepatocellular carcinoma.
authors.affiliation: Gastroenterological Center, Yokohama City University Medical Center.
authors.forename: Manabu
authors.initials: M
authors.lastname: Morimoto
authors.forename: Kazushi
authors.initials: K
authors.lastname: Numata
authors.forename: Kazuya
authors.initials: K
authors.lastname: Sugimori
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Shirato
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kokawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Oka
authors.forename: Mitsunari
authors.initials: M
authors.lastname: Hirao
authors.forename: Kingo
authors.initials: K
authors.lastname: Hirasawa
authors.forename: Ryonpo
authors.initials: R
authors.lastname: Ko
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Saitou
authors.forename: Toshio
authors.initials: T
authors.lastname: Imada
authors.forename: Katsuaki
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017115:Catheter Ablation; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D000431:Ethanol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007267:Injections; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000431:Ethanol